FOLIGRAF 75-MHP

Indications

• Folic acid deficiency
• Megaloblastic anemia due to folate deficiency
• Prevention of neural tube defects in pregnancy
• Supplementation during pregnancy and lactation
• Hyperhomocysteinemia

Dosage

Children: Refer to BNF for Children for specific dosing guidance, generally determined by age and indication.

Adults: Refer to BNF for specific dosing guidance, typically ranging from 400 mcg to 5 mg per day depending on the indication.

Mechanism of action

Folic acid is converted in the body to tetrahydrofolate, which is a coenzyme involved in the transfer of one-carbon units in various metabolic processes. This activity is critical for the synthesis of nucleic acids and amino acids, thus supporting cell division and growth. It also plays a role in the metabolism of homocysteine, converting it to methionine, thereby influencing cardiovascular health.

Pharmacodynamics

Folic acid assists in the formation of red blood cells, the synthesis of DNA and RNA, and the metabolism of amino acids. Its deficiency can lead to megaloblastic anemia, characterized by the production of large, immature red blood cells. Adequate levels of folic acid are essential for the prevention of neural tube defects during pregnancy.

Pharmacokinetics

Folic acid is rapidly absorbed in the intestine, with peak plasma concentrations typically occurring within 1-2 hours after oral administration. It is extensively metabolized in the liver to its active forms. Folic acid has a relatively short half-life, approximately 6 hours, and is primarily excreted in urine. The body stores small amounts of folate, which can be depleted in cases of inadequate dietary intake.

Adverse effects

• Allergic reactions
• Nausea
• Gastrointestinal disturbances
• Skin rash

Precautions

• Use with caution in patients with a history of allergic reactions to folic acid or its components
• Monitor for signs of folate deficiency in patients with malabsorption syndromes

Pregnancy

Folic acid is essential during pregnancy for fetal development, particularly in preventing neural tube defects. It is often recommended that women take folic acid supplements before conception and during pregnancy.

Breast-feeding

Folic acid is excreted in breast milk, but it is generally considered safe during breastfeeding as it is important for the infant's development.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Tablets
• Capsules
• Oral solutions

Indications

• Menopausal symptoms (e.g., hot flashes, vaginal dryness)
• Hypogonadism
• Thyroid disorders (e.g., hypothyroidism)
• Adrenal insufficiency
• Growth hormone deficiency
• Polycystic ovary syndrome (PCOS)

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines, as these depend on the type of hormone and the condition being treated.

Adults: Refer to the specific hormone type and formulation for dosing guidance in adults, as dosages may vary significantly based on individual patient needs and specific conditions being treated.

Mechanism of action

Hormones exert their effects through binding to specific receptors on target cells, initiating a cascade of intracellular signaling pathways. This may involve the activation of gene expression, modulation of enzyme activity, or alteration of cell membrane permeability. The specific mechanism varies depending on the type of hormone and its target tissues.

Pharmacodynamics

Hormones have varied effects depending on their class and the target tissues involved. They can influence metabolic pathways, regulate growth and development, and affect mood and cognition. Hormones typically act through either genomic mechanisms, involving changes in gene transcription, or non-genomic pathways, which may involve rapid signaling via second messengers.

Pharmacokinetics

The pharmacokinetics of hormones vary widely based on their chemical structure, route of administration, and formulation. Generally, hormones are absorbed into circulation after administration, with peak plasma concentrations occurring at variable times depending on the specific hormone. They may be metabolized in the liver or other tissues, with elimination typically occurring through renal or biliary excretion. Half-lives can range from minutes to hours, influencing dosing frequency.

Interactions

• antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) + hormone replacement therapy: Unknown (decreases effects)
• bosentan + hormone replacement therapy: Unknown (decreases effects)
• ritonavir + hormone replacement therapy: Unknown (decreases effects)
• modafinil + hormone replacement therapy: Unknown (decreases effects)
• rifamycins + hormone replacement therapy: Unknown (decreases effects)
• St John's Wort + hormone replacement therapy: Unknown (decreases efficacy)
• etoricoxib + hormone replacement therapy: Unknown (increases exposure)

Indications

• Attention Deficit Hyperactivity Disorder (ADHD)
• Narcolepsy
• Obesity (as part of a comprehensive weight management program)
• Treatment-resistant depression
• Cognitive enhancement in certain disorders

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines based on age and weight.

Adults: Refer to the specific BNF for individual stimulant medications for appropriate dosing guidelines.

Mechanism of action

Stimulants enhance the release of neurotransmitters such as dopamine and norepinephrine in the brain. They inhibit the reuptake of these neurotransmitters, leading to increased synaptic concentrations and prolonged effects. This mechanism is particularly relevant in the treatment of ADHD, where increased dopamine activity in the prefrontal cortex can improve attention and behavior regulation.

Pharmacodynamics

Stimulants generally exert their effects by increasing neurotransmitter availability in the synaptic cleft, leading to enhanced neuronal firing rates. This results in improved cognitive function, mood elevation, and increased physical activity. The specific pharmacodynamic profile can vary between different stimulant medications, with some exhibiting a more pronounced effect on dopamine versus norepinephrine pathways.

Pharmacokinetics

Stimulants are typically well absorbed in the gastrointestinal tract and may have varying half-lives depending on the formulation (immediate vs extended release). They are metabolized primarily in the liver, and their elimination is often through the kidneys. The onset of action can range from minutes to hours, with effects lasting from a few hours to over 12 hours in some extended-release forms.

Pregnancy

The use of stimulating agents during pregnancy should be approached with caution due to potential risks to fetal development. It is essential to weigh the benefits against possible adverse effects.

Breast-feeding

Caution is advised when using stimulating agents while breastfeeding, as they may pass into breast milk and affect the infant.

Storage

Store in a cool, dry place away from direct sunlight. Ensure the container is tightly closed to maintain stability.